Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis - Top-Institutions - MDSpire

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

  • By

  • Xiao Ma

  • Gaofeng Li

  • Heng Li

  • July 16, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Sun Yat-sen University Cancer Center
    Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong

    Key Differentiators

    • Oncology

  • #2

    Shanghai Chest Hospital
    Shanghai Chest Hospital

    Shanghai, Shanghai

    Key Differentiators

    • Oncology

  • #3

    Winship Cancer Institute
    Winship Cancer Institute

    Atlanta, Georgia

    Key Differentiators

    • Oncology

  • #4

    National Taiwan University College of Medicine
    National Taiwan University College of Medicine

    Taipei, Taiwan

    Key Differentiators

    • Oncology

  • #5

    Vall d’Hebron University
    Vall d’Hebron University

    Barcelona, Catalonia

    Key Differentiators

    • Oncology

Original Source(s)

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

  • by Xiao Ma, Gaofeng Li, Heng Li

  • July 16, 2026

Related Content

Evaluation of an interpretable deep-learning model for the automated plan review of intensity-modulated radiation therapy

Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

Functional brain connectivity correlates of pain relief during virtual reality exposure in cancer patients